HOBOKEN, N.J. and NEWCASTLE, United Kingdom (PRWEB)
December 03, 2020
Genesis Research LLC (GR), a Value Demonstration Company providing Real World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services to the health and life sciences industries, announced today that it has merged with SIRIUS Market Access Ltd (“SIRIUS”).
Headquartered in Hoboken, NJ USA, GR provides end-to-end strategy, evidence generation, and communication services powered by its deep expertise in Real World Evidence (RWE). GR client solutions incorporate data strategy, comprehensive RWE partnerships, data science and analytics, economic modeling, biostatistics, digital platforms, and scientific communications. Headquartered in Newcastle, United Kingdom, SIRIUS provides innovative expertise in Market Access Strategy, Health Technology Assessments, and Value Communications to life science companies in Europe and worldwide.
“As one of the fastest-growing Market Access companies in our industry – with an amazing corporate culture, a sterling reputation for quality and a client-first mentality – we could not imagine a better European partner,” said Frank A. Corvino, Chief Executive Officer and Co-Founder of Genesis Research. “As one Company, with our expanded capabilities and geographic reach, GR will be uniquely positioned to provide comprehensive value demonstration to our clients across the product life cycle.”
“We are extremely proud to be forming one company with Genesis Research. Over the past few years, we have built a strong partnership, and in the process learned how we share the same values in bringing the highest quality, integrity and an industry leading level of expertise to our clients,” said Stephen Ralston, Founding Partner at SIRIUS. “Genesis is an industry leader in providing RWE solutions; they are a perfect partner for SIRIUS, and as one company, we are excited to better serve our global clients,” added Mr. Ralston, the newly appointed Chief Commercial Officer of Genesis Research.
Genesis Research is a well-respected, trusted functional service provider that has been serving life sciences companies across multiple therapeutic areas including Oncology, Central Nervous System (CNS), Immunology, and Inflammation. GR’s quality research and novel client engagement model allow life sciences companies to better understand and articulate their products’ value. GR’s work facilitates increased access to treatment, optimal clinical management strategies, and improvements in quality-of-life for patients, and decreased burden on healthcare systems.
Steve Arikian, Chairman and Co-Founder of Genesis Research, added, “Years ago, we were fortunate to begin a partnership with SIRIUS that arose from our shared values and their impressive reputation. Now, formally as one team, we will lead the market by meeting our clients’ growing requirements for unified value demonstration services.”
About Genesis Research:
Genesis Research is a Value Demonstration Company that serves as a Functional Service Provider to the Life Sciences industry, delivering Real World Evidence services to satisfy regulatory, payer, and commercial requirements throughout the product lifecycle. As a leader in evidence development and communication, Genesis Research also supports clients with unique services such as rapid response analytics, outcomes simulation, and payer data collaboration. For more information about Genesis Research, please visit http://www.GenesisRG.com.
About SIRIUS Market Access:
SIRIUS, headquartered in Newcastle, UK, provides leading market access services to the pharmaceutical, biotechnology and device industry, both in the UK and worldwide. The SIRIUS team brings a new level of expertise in market access, HTA, and value communications. SIRIUS recognizes that success in market access requires a thorough understanding of the payer environment, developing innovative strategies and compelling evidence that can be packaged together and clearly communicated to all stakeholders. For more information about SIRIUS, please visit https://siriusmarketaccess.com.
Share article on social media or email: